Medication info
Esomeprazole Magnesium 40 mg Tablet

Esomeprazole Magnesium 40 mg Tablet

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›43.38mg / 1 tablet
Manufacturer / importer
Hanin Pharmaceutical Co., Ltd.
Appearance
Pink oblong film-coated tablet
Packaging
28 tablets (14 tablets/PTP × 2)
Approval status
Active

MFDS item code 201701081 · Approved 2017.02.28 · Insurance code 657203020

Summary

Main use
Treatment of gastrointestinal disorders (e.g., reflux and ulcers), Helicobacter pylori eradication, and Zollinger–Ellison syndrome
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. In patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed administration is not recommended to control recurrent symptoms. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer 20 mg of this medicine with 1 g of amoxicillin and 500 mg of clarithromycin twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with use of nonsteroidal anti-inflammatory drugs (non-COX-2-selective or COX-2-selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg/day. Doses exceeding 80 mg/day should be divided into 2 doses. 6) Maintenance therapy following initiation of intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following initiation of intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. 4. Renal impairment No dosage adjustment is necessary. Use with caution because experience in patients with severe renal impairment is limited. 5. Hepatic impairment No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dosage adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 3. Children under 12 years of age There is no experience with administering this drug to children under 12 years of age.

Ingredients

Manufacturer
Hanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastrointestinal disorders (e.g., reflux and ulcers), Helicobacter pylori eradication, and Zollinger–Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive esophagitis, and it is also effective for long-term maintenance therapy to prevent recurrence in patients with esophagitis. It is additionally utilized for the treatment of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection, as well as for their prevention of recurrence. It aids in alleviating symptoms such as pain, discomfort, and burning sensation in the upper gastrointestinal tract that can occur when taking non-steroidal anti-inflammatory drugs, and is used for the treatment and prevention of gastric and duodenal ulcers. It is also applied in the treatment of Zollinger-Ellison syndrome and for maintenance therapy following intravenous administration, thus assisting in the management of various gastrointestinal diseases. Overall, this drug is used to improve and treat symptoms related to various diseases of the stomach and esophagus.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. In patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed administration is not recommended to control recurrent symptoms. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer 20 mg of this medicine with 1 g of amoxicillin and 500 mg of clarithromycin twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with use of nonsteroidal anti-inflammatory drugs (non-COX-2-selective or COX-2-selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring continued treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg/day. Doses exceeding 80 mg/day should be divided into 2 doses. 6) Maintenance therapy following initiation of intravenous treatment to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following initiation of intravenous treatment to prevent rebleeding from gastric or duodenal ulcers. 4. Renal impairment No dosage adjustment is necessary. Use with caution because experience in patients with severe renal impairment is limited. 5. Hepatic impairment No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients No dosage adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 3. Children under 12 years of age There is no experience with administering this drug to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. For example, individuals allergic to this medication or its components, or those who have previously experienced hypersensitivity reactions to similar drugs, should avoid taking it. Caution is also required for those with allergies to penicillin or macrolide antibiotics when used in combination. Patients currently on specific heart-related medications or with a history of myocardial infarction, as well as nursing women, are also advised against using this drug. This medication may cause various side effects, so any symptoms occurring should be immediately discussed with healthcare professionals. Gastrointestinal symptoms such as headache, abdominal pain, diarrhea, and vomiting may commonly occur, while rarer serious reactions like blood abnormalities, skin rashes, and difficulty in breathing have also been reported. Long-term use may lead to decreased levels of magnesium, calcium, and potassium, requiring regular testing. This drug inhibits gastric acid secretion and may increase the risk of bacterial growth in the stomach, so if diarrhea persists, infection should be checked. Additionally, long-term use may increase the risk of fractures, and caution is warranted for those at risk of osteoporosis. This medication may interact with several other drugs, so patients taking other medications must inform their physician or pharmacist. In particular, dosage adjustments or monitoring may be necessary when used with anticoagulants, antiviral agents, certain antibiotics, and anticonvulsants. Due to limited safety data during pregnancy, those who are pregnant or planning to become pregnant should consult with their doctor before use. If nursing, it is recommended to avoid this medication as it may be transmitted through breast milk. In the case of overdose, there is no specific antidote; symptomatic treatment is required, and the medication should be kept out of the reach of children to prevent accidents.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Lyell's syndrome, acute generalized pustular psoriasis, eosinophilia and systemic symptoms-associated drug reaction, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distention, allergic reaction, back pain, chest pain, sternal pain, facial swelling, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal dysfunction, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, black stools, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased blood gastrin, tongue disorders, tongue edema, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, impaired liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, xerostomia, vitamin B12 deficiency, weight gain, weight loss, worsening of arthritis, arthropathy, convulsion, fibromyalgia syndrome, hernia, rheumatic polymyalgia, anorexia, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, worsening of migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, worsening of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, abnormal olfaction, loss of taste, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urination frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should ideally be maintained between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink oblong film-coated tablet

Package unit

28 tablets (14 tablets/PTP × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.